Discover the Dynamic Landscape of GLP-1 Drug Development

The company has entered into a binding agreement with Molteni Farmaceutici regarding exclusive rights to commercialize BupiZenge in Europe.

Manufacturers’ perspectives on mechanisms for coping with uncertainty.

The Board of Directors of Flerie and the Board of Directors of Toleranzia have adopted a plan to join forces through a statutory merger between the companies in accordance with the Swedish Companies Act.

A meeting organized by PharmaLex and the Life Science Cluster in Norway on February 27 2025 brought together experts eager to share and learn more about the European Union’s Health Technology Assessment Regulation (HTAR), its requirements and challenges, and its adoption and impact.

Immunovia has announced additional results from the VERIFI study of its next-generation pancreatic cancer test, strengthening the company’s position as it prepares to launch the pancreatic cancer blood test commercially. 

Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.

Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary, The United Bio-Technology (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.